Icon Bioscience - Company & Market Research Reports

Icon Bioscience was founded in 2004, the headquarters are in Sunnyvale, California. This company focuses on using the verisome technology to approved or in market ophthalmic agents. They improve existing eye disease treatments. Icon’s leading product ‘Dexycu’ has completed phase III and an NDA is planned for 2017. It is used to reduce inflammation from cataract surgery. They target many diseases such as: ophthalmic indications, including glaucoma, macular edema, inflammation/infection associated with cataract surgery, and age-related macular degeneration.

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities - Product Thumbnail Image

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities

  • Report
  • 144 Pages
Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition) - Product Thumbnail Image

Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)

  • Report
  • 275 Pages
From
Ophthalmology Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Ophthalmology Drug Development Pipeline Review, 2016

  • Report
  • 633 Pages
From
Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018 - Product Thumbnail Image

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 52 Pages
From
Uveitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 195 Pages
From
Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026 - Product Thumbnail Image

Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026

  • Report
  • 228 Pages
From
Glaucoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 299 Pages
From
Age Related Macular Degeneration - Pipeline Review, H2 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H2 2017

  • Drug Pipelines
  • 537 Pages
From
Age Related Macular Degeneration - Pipeline Review, H1 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H1 2017

  • Drug Pipelines
  • 527 Pages
From
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

  • Drug Pipelines
  • 136 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

  • Drug Pipelines
  • 267 Pages
From
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016 - Product Thumbnail Image

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

  • Drug Pipelines
  • 141 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016

  • Drug Pipelines
  • 254 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015

  • Drug Pipelines
  • 248 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015

  • Drug Pipelines
  • 226 Pages
From
Cystoid Macular Edema Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Cystoid Macular Edema Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 86 Pages
From
Ocular Inflammation - Pipeline Review, H1 2014 - Product Thumbnail Image

Ocular Inflammation - Pipeline Review, H1 2014

  • Drug Pipelines
  • 98 Pages
From
Global Retinoblastoma Treatment Market - Growth, Trends and Forecasts 2017 - 2022 - Product Thumbnail Image

Global Retinoblastoma Treatment Market - Growth, Trends and Forecasts 2017 - 2022

  • Report
  • 211 Pages
From
Acquisition of Icon Bioscience Inc by PSivida Corp Call - pSivida Corp., - Earnings Transcript - Product Thumbnail Image

Acquisition of Icon Bioscience Inc by PSivida Corp Call - pSivida Corp., - Earnings Transcript

  • Earnings Transcript
  • 20 Results (Page 1 of 1)
Loading Indicator
adroll